Skip to main content

Hikma releases dacarbazine


Hikma is offering dacarbazine for injection in a dosage strength of 200 mg.

The product is indicated in the treatment of metastatic malignant melanoma, and Hodgkin’s disease as a second-line therapy when used in combination with other effective agents.

Dacarbazine for injection, 200 mg had a market value of approximately $2 million in the 12 months ending May 2020, according to IQVIA.

This ad will auto-close in 10 seconds